CS
WHWK

Credit Suisse’s Whitehawk Therapeutics WHWK Stock Holding History

Credit Suisse’s Portfolio WHWK Stock Details WHWK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1
Closed -$13 – 3788
2022
Q4 		$13 Sell
1
-78
-99% -$1.02K ﹤0.01% 3708
2022
Q3 		$1K Buy
79
+72
+1,029% +$946 ﹤0.01% 3957
2022
Q2 		$0 Buy
+7
New +$104 ﹤0.01% 4394

Other funds holding WHWK

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Credit Suisse's WHWK Position: Q1 2023 in Review

Credit Suisse sold out of Whitehawk Therapeutics (WHWK) in Q1 2023, closing a stake of 1 share — an estimated $13 sold.

Credit Suisse first reported a position in WHWK in Q2 2022 and held it in 3 quarters. The position peaked at $1K in Q3 2022. 70 funds tracked by Wall St. Rank hold WHWK as of Q1 2023.

  • Credit Suisse reported no remaining Whitehawk Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Credit Suisse sold 1 Whitehawk Therapeutics share in Q1 2023, an estimated $13.
  • Credit Suisse first reported a position in Whitehawk Therapeutics in Q2 2022 and held it in 3 quarters.
  • Credit Suisse's Whitehawk Therapeutics position peaked at $1K in Q3 2022.
  • 70 funds tracked by Wall St. Rank held Whitehawk Therapeutics as of Q1 2023.

Based on Credit Suisse's 13F filing for Q1 2023, filed 10 May 2023.